- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00633984
D-Cycloserine Enhancement of Exposure in Social Phobia
The purpose of this study is to test a drug called d-cycloserine to see if it can help people with a condition called social phobia. Social phobia is also called "social anxiety disorder." Social phobia is a constant fear of social or performance situations. Social situations include group gatherings of any kind. Performance situations might include times when a person would have to do something in public, such as speak up in class or at a meeting. A person with this condition worries about being embarrassed, or about other people's opinions. People with social phobia usually feel extremely anxious (nervous and worried) about being the focus of attention. They often avoid social and performance situations. This behavior can have a negative effect on the quality of their lives and relationships.
In this study, we want to find out if d-cycloserine can help control social phobia when the drug is added to the standard treatment for this condition. The standard treatment is cognitive-behavior therapy (CBT). CBT is a form of talk therapy involving discussion with a therapist, along with practicing the feelings or events that the person finds frightening.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Inclusion criteria:
- Age 18 or older
- Primary diagnosis of SAD
- Physical examination, electrocardiogram, and laboratory findings without clinically significant abnormalities.
- Willingness and ability to comply with the requirements of the study protocol.
Diagnostic Exclusion Criteria:
- A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders or obsessive-compulsive disorder; an eating disorder in the past 6 months; organic brain syndrome, mental retardation or other cognitive dysfunction that could interfere with capacity to engage in therapy; a history of substance or alcohol abuse or dependence (other than nicotine) in the last 6 months or otherwise unable to commit to refraining from alcohol use during the acute period of study participation.
- Patients with posttraumatic stress disorder within the past 6 months are excluded. Entry of patients with other mood or anxiety disorders will be permitted if the social anxiety disorder is judged to be the predominant disorder, in order to increase accrual of a clinically relevant sample. Patients with significant suicidal ideation (MADRS item 10 score > 3) or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.
- Patients must be off concurrent psychotropic medication (e.g., antidepressants, anxiolytics, beta blockers) for at least 2 weeks prior to initiation of randomized treatment.
- Significant personality dysfunction likely to interfere with study participation.
- Serious medical illness or instability for which hospitalization may be likely within the next year.
- Patients with a current or past history of seizures
- Pregnant women, lactating women, and women of childbearing potential who are not using medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months).
- Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of the GSAD is excluded. Prohibited psychotherapy includes CBT or psychodynamic therapy focusing on exploring specific, dynamic causes of the phobic symptomatology and provides management skills. General supportive therapy initiated > 3 months prior is acceptable.
- Prior non-response to adequately-delivered exposure (i.e., as defined by the patient's report of receiving specific and regular exposure assignments as part of a previous treatment) will exclude participants from the study.
- Patients with a history of head trauma causing loss of consciousness, seizure or ongoing cognitive impairment.
- Patients receiving isoniazid.
- Patients unable to understand study procedures and participate in the informed consent process.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 4
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02114
- Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Male or female outpatients > 18 years of age with a primary psychiatric diagnosis (designated by the patient as the most important source of current distress) of generalized social anxiety disorder (GSAD) as defined by DSM-IV criteria.
- A total score > 60 on the LSAS.
- Physical examination, electrocardiogram, and laboratory findings without clinically significant abnormalities.
- Willingness and ability to comply with the requirements of the study protocol.
Exclusion Criteria:
- A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders or obsessive-compulsive disorder; an eating disorder in the past 6 months; organic brain syndrome, mental retardation or other cognitive dysfunction that could interfere with capacity to engage in therapy; a history of substance or alcohol abuse or dependence (other than nicotine) in the last 6 months or otherwise unable to commit to refraining from alcohol use during the acute period of study participation.
- Patients with posttraumatic stress disorder within the past 6 months are excluded. Entry of patients with other mood or anxiety disorders will be permitted if the social anxiety disorder is judged to be the predominant disorder, in order to increase accrual of a clinically relevant sample. Patients with significant suicidal ideation (MADRS item 10 score > 3) or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.
- Patients must be off concurrent psychotropic medication (e.g., antidepressants, anxiolytics, beta blockers) for at least 2 weeks prior to initiation of randomized treatment.
- Significant personality dysfunction likely to interfere with study participation.
- Serious medical illness or instability for which hospitalization may be likely within the next year.
- Patients with a current or past history of seizures
- Pregnant women, lactating women, and women of childbearing potential who are not using medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months).
- Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of the GSAD is excluded. Prohibited psychotherapy includes CBT or psychodynamic therapy focusing on exploring specific, dynamic causes of the phobic symptomatology and provides management skills. General supportive therapy initiated > 3 months prior is acceptable.
- Prior non-response to adequately-delivered exposure (i.e., as defined by the patient's report of receiving specific and regular exposure assignments as part of a previous treatment) will exclude participants from the study.
- Patients with a history of head trauma causing loss of consciousness, seizure or ongoing cognitive impairment.
- Patients receiving isoniazid.
- Patients unable to understand study procedures and participate in the informed consent process.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Aktywny komparator: Cognitive Behavioral Group Therapy + D-Cycloserine
Participants received Cognitive Behavioral Group Therapy and 50mg D-Cycloserine.
|
The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each.
During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions.
As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine.
A physician will be available in the unlikely event that a patient begins to experience side effects.
Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
|
Komparator placebo: Cognitive Behavioral Group Therapy + Placebo
Participants received Cognitive Behavioral Group Therapy and 50mg Placebo.
|
The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each.
During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions.
As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo.
A physician will be available in the unlikely event that a patient begins to experience side effects.
Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Liebowitz Social Anxiety Scale (LSAS)
Ramy czasowe: Week 13
|
The Liebowitz Social Anxiety Scale (LSAS) is a 24-item measure designed to assess both fear and avoidance of social and performance situations occurring in the last week.
Each item is rated from 0-3 for both fear and avoidance with a possible score of 144; 55-65 Moderate social phobia, 65-80 Marked social phobia, 80-95 Severe social phobia, and Greater than 95 - Very severe social phobia.
Remission was defined as a score of < 30 on the Liebowitz Social Anxiety Scale
|
Week 13
|
CGI - Clinical Global Impression of Improvement
Ramy czasowe: Week 13
|
The Clinician Global Impression-Improvement Scale (CGI-I) is a clinician-rated instrument used to assess global severity of symptoms.
The CGI-I ranges from 1 ("very much improved") to 7 ("very much worse").
Response and remission was defined as an improvement score of 1 ("very much improved") or 2 ("much improved") on the CGI-I.
|
Week 13
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Mark H Pollack, MD, mpollack@partners.org
- Główny śledczy: Stefan Hofmann, shofmann@bu.edu
Publikacje i pomocne linki
Publikacje ogólne
- Zalta AK, Dowd S, Rosenfield D, Smits JA, Otto MW, Simon NM, Meuret AE, Marques L, Hofmann SG, Pollack MH. Sleep quality predicts treatment outcome in CBT for social anxiety disorder. Depress Anxiety. 2013 Nov;30(11):1114-20. doi: 10.1002/da.22170. Epub 2013 Aug 26.
- Smits JA, Rosenfield D, Otto MW, Marques L, Davis ML, Meuret AE, Simon NM, Pollack MH, Hofmann SG. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res. 2013 Oct;47(10):1455-61. doi: 10.1016/j.jpsychires.2013.06.020. Epub 2013 Jul 16.
- Hofmann SG, Smits JA, Rosenfield D, Simon N, Otto MW, Meuret AE, Marques L, Fang A, Tart C, Pollack MH. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013 Jul;170(7):751-8. doi: 10.1176/appi.ajp.2013.12070974.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Zaburzenia psychiczne
- Zaburzenia fobiczne
- Zaburzenia lękowe
- Fobia społeczna
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Antymetabolity
- Środki przeciwbakteryjne
- Środki przeciwgruźlicze
- Antybiotyki, Przeciwgruźlicze
- Środki przeciwinfekcyjne, układ moczowy
- Środki nerkowe
- Cykloseryna
Inne numery identyfikacyjne badania
- 2007-P-000386
- R01MH075889 (Grant/umowa NIH USA)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Fobia społeczna
-
Jagannadha R AvasaralaZakończonyStwardnienie rozsiane | Zapalenie nerwu wzrokowego | Neuromyelitis Optica Spectrum Disorder Atak | Zapalenie nerwu wzrokowego i spektrum zaburzeń nerwu wzrokowego Nawrót | Neuromyelitis Optica Spectrum Disorder ProgresjaStany Zjednoczone
-
Experimental and Clinical Research Center, a cooperation...RekrutacyjnyStwardnienie rozsiane | Choroby demielinizacyjne | Zapalenie nerwu wzrokowego | Neuromyelitis Optica Spectrum Disorder Atak | Choroba związana z przeciwciałami glikoproteinowymi mieliny oligodendrocytówWłochy, Stany Zjednoczone, Argentyna, Australia, Botswana, Brazylia, Kolumbia, Dania, Francja, Niemcy, Indie, Izrael, Japonia, Republika Korei, Hiszpania, Zjednoczone Królestwo, Zambia
Badania kliniczne na Cognitive Behavioral Group Therapy (CBGT)
-
Karadeniz Technical UniversityZakończonyHemodializa | Samotność | Szczęście | Dostosowanie | Terapia wspomagana przez zwierzęta | ObjawIndyk
-
Shandong UniversityJeszcze nie rekrutacjaInfekcja Helicobacter PyloriChiny